Prosecution Insights
Last updated: November 20, 2026
Application No. 18/615,330

DEVELOPMENT AND OPTIMIZATION OF THIOCHROMENOTHIAZOLE-BASED MSUT2 INHIBITORS AS CANDIDATES FOR THE TREATMENT OF TAUOPATHY

Non-Final OA §102§112
Filed
Mar 25, 2024
Priority
Mar 24, 2023 — provisional 63/454,455
Examiner
ROMERO, KRISTEN WANG
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The United States Government as represented by the Department of Veterans Affairs
OA Round
2 (Non-Final)
70%
Grant Probability
Favorable
2-3
OA Rounds
6m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 70% — above average
70%
Career Allowance Rate
38 granted / 54 resolved
+10.4% vs TC avg
Strong +31% interview lift
Without
With
+30.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
48 currently pending
Career history
96
Total Applications
across all art units

Statute-Specific Performance

§101
4.1%
-35.9% vs TC avg
§103
20.4%
-19.6% vs TC avg
§102
19.4%
-20.6% vs TC avg
§112
39.5%
-0.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 54 resolved cases

Office Action

§102 §112
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims and Response to Amendments. The amendments filed on August 21, 2026 have been acknowledged and entered. Claims 1-20 are pending. Status of Priority The present application claims the benefits of priority to U.S. Provisional Application No. 63/454,455 filed on March 24, 2023. Specification - Disclosure The specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant’s cooperation is requested in correcting any errors of which applicant may become aware in the specification. Withdrawn Rejections Applicant is notified that any outstanding rejection or objection that is not expressly maintained in this office action has been withdrawn or rendered moot in view of applicant' s amendments and/or remarks. Claim Objections Claim 16 is objected to because of the following informalities: Claim 16 is further objected to for the following reasons: Rule 1.141(a) states: Two or more independent and distinct inventions may not be claimed in one national application, except that more than one species of an invention, not to exceed a reasonable number, may be specifically claimed in different claims in one national application, provided the application also includes an allowable claim generic to all the claimed species and all the claims to species in excess of one are written in dependent form (§ 1.75) or otherwise include all the limitations of the generic claim. Claim 16 claims a large number of species of the generic claim, but in independent format. Multiple inventions may not be claimed in a single application unless they are species claims which are dependent upon the larger, generic claim. In the past, the Office has held a “reasonable number” to be five (5) species. The present claim contains well over this number of species. One could envision forty pages of species compounds in a single claim which is not dependent upon any genus claim. This would cause undue burden to the Office in examining such a large claim. Therefore, it is recommended that Claim 16 either be dependent from a larger, genus claim, or, that claim 16 incorporate all of the limitations of the genus claim. Applicants are invited to contact the examiner if further clarification is needed. No new matter is permitted. Applicant responded to the above objection by stating: “Rule 1.141(a) addresses multiple claims reciting distinct inventions, not a single claim enumerating alternative species” and that the “rule does not purport to regulate the internal structure of a single claim” (see Applicant Remarks, filed 08/21/2026, pg. 17). The objection to claim 16 is maintained, with clarification provided below: As stated above, according to rule 1.141(a), “Two or more independent and distinct inventions may not be claimed in one national application.” Currently, there are multiple claims reciting distinct inventions. For example: One of these inventions is a compound having a structure represented by the formula recited in instant claim 1. Another invention is a compound having a structure represented by any of the specific structures recited in instant claim 16. Furthermore, the compounds disclosed in instant claim 16 do not all share the same core structure. Some of those core structures are shown below: PNG media_image1.png 122 146 media_image1.png Greyscale , PNG media_image2.png 273 306 media_image2.png Greyscale , PNG media_image3.png 314 293 media_image3.png Greyscale , PNG media_image4.png 355 351 media_image4.png Greyscale , PNG media_image5.png 306 354 media_image5.png Greyscale , PNG media_image6.png 235 274 media_image6.png Greyscale , and PNG media_image7.png 239 278 media_image7.png Greyscale among others. Therefore, there is a search burden to search compounds possessing many different core structures. Because the instant application is claiming two or more independent and distinct inventions (as explained in points 1 and 2 above), one of these claims comprising subject matter of a distinct invention should be amended. For example, claim 16 can be amended such that claim 16 would only include compounds that are encompassed by instant claim 1. Making such an amendment would result in both claims 1 and 16 belonging under the same claimed invention and, therefore, the requirements of rule 1.141(a) would be satisfied. Appropriate correction is required. --------------- Rejections Necessitated by Applicant Amendment --------------- Claim Rejections - 35 USC § 112(a) The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Written Description Claims 17-20 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Claim 17 has been amended to include a definition for R10: “…wherein R10 is selected from hydrogen and C1-C4 alkyl…” Applicant states that support for this amendment can be found in, for example, paragraphs [0005]-[0006] of the as filed application. However, paragraphs [0005]-[0006] of the instant specification provides support for the compound recited in instant claim 1. Support for the compound recited in instant claim 17 is provided in paragraph [00247] of the instant specification. Note that the compound recited in instant claim 1 is different from the compound recited in instant claim 17. In para. 00247, it does not define R10 for the compound recited in instant claim 17. Para. 00247 defines all other variables encompassed by the formula in instant claim 17 except for R10. Therefore, the definition of R10 in claim 17 does not have written description support in the specification and claim 17 fails to comply with the written description requirement. Claims 18-20, which are dependent on claim 17, are also rejected for further requiring and/or reciting elements that fail to comply with the written description requirement. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-15 and 17-20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 recites: “…provided that when R2 is hydrogen, then A is *-CO2CH2N(R10)-**…” on pg. 3 of the claim set. However, earlier in claim 1 (on pg. 2), R2 is defined to be C2-C8 alkenyl, C2-C8 alkynyl, -(C1-C4 alkyl)SO3H, or Ar1 (i.e., R2 cannot be H). Therefore, this inconsistency renders the scope of claim 1 unclear. Claims 2-15 which are dependent on claim 1, are also rejected for further requiring and/or reciting the indefinite limitation of claim 1. Regarding claims 17-20: The limitation “a neurodegenerative disorder associated with dysregulation of MSUT2 signaling” renders the scope of the claim indefinite because the claim defines the neurodegenerative disorder only by its functional relationship to MSUT2, without identifying which neurodegenerative disorders are encompassed or providing an objective standard for determining when a neurodegenerative disorder is sufficiently “associated” with dysregulation of MSUT2 signaling to fall within the scope of the claim. Furthermore, neither the specification, nor the claim, defines what type of MSUT2 signaling is considered dysregular. It is, therefore, unclear whether the limitation only encompasses neurodegenerative disorders that were established to be directly driven by dysregulation of MSUT2 signaling as of the effective filing date, or does it also encompass neurodegenerative disorders that may subsequently be discovered or later determined to involve dysregulation of MSUT2 signaling upon future scientific investigation. For these above reasons, the boundaries of claim 17 is rendered vague and indefinite. Claims 18-20, which are dependent on claim 17, are also rejected for further requiring and/or reciting the indefinite limitation of claim 17. Claim Rejections - 35 USC § 112(d) The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 11 and 14 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 11 recites: “…wherein R2 is selected from C1-C8 alkyl, …” Claim 11 is dependent on claim 1 which does not recite that R2 can be C1-C8 alkyl. Thus, claim 11 fails to further limit the subject matter of the claim upon which it depends and, instead, broadens the scope of claim 1. Claim 14 recites the following compound: PNG media_image8.png 187 225 media_image8.png Greyscale . In this compound, R2 is a C4 alkyl. Claim 14 is dependent on claim 1 which does not recite that R2 can be C1-C8 alkyl. Thus, claim 14 fails to further limit the subject matter of the claim upon which it depends and, instead, broadens the scope of claim 1. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Note on 35 USC § 102 and 103 Rejections In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim 16 is rejected under 35 U.S.C. 102 as being anticipated by: STN registry entry, RN 2010-06-2 entered into the database on November 16, 1984: PNG media_image9.png 868 774 media_image9.png Greyscale ------------------------------- Added Rejections ------------------------------- Claim Rejections – Improper Markush Grouping Claim 16 is rejected on the judicially-created basis that it contains an improper Markush grouping of alternatives. See In re Harnisch, 631 F.2d 716, 721-22 (CCPA 1980) and Ex parte Hozumi, 3 USPQ2d 1059, 1060 (Bd. Pat. App. & Int. 1984). The improper Markush grouping includes species of the claimed invention that do not share both a substantial structural feature and a common use that flows from the substantial structural feature. A Markush claim contains an “improper Markush grouping” if: (1) the species of the Markush group do not share a single structural similarity,” or (2) the species do not share a common use. Members of a Markush group share a "single structural similarity” when they belong to the same recognized physical or chemical class or to the same art-recognized class. Members of a Markush group share a common use when they are disclosed in the Specification or known in the art to be functionally equivalent (see Federal Register, Vol. 76, No. 27, Wednesday, February 9, 2011, p. 7166, left and middle columns, bridging paragraph). The members of the improper Markush grouping do not share a substantial feature and/or a common use that flows from the substantial structural feature for the following reasons: The claimed Markush group encompasses compounds having substantially different core structures. Some example core structures are depicted below: PNG media_image1.png 122 146 media_image1.png Greyscale , PNG media_image2.png 273 306 media_image2.png Greyscale , PNG media_image3.png 314 293 media_image3.png Greyscale , PNG media_image4.png 355 351 media_image4.png Greyscale , PNG media_image5.png 306 354 media_image5.png Greyscale , PNG media_image6.png 235 274 media_image6.png Greyscale , and PNG media_image7.png 239 278 media_image7.png Greyscale among others. Clearly no ‘‘single structural similarity’’ can be seen amongst the different core structures described above which may be individual or fused ring structures linked to other moieties wherein, the rings possess different molecular geometries as well as electronic (and, therefore, chemical) properties. In response to this rejection, Applicant should either amend the claim(s) to recite only individual species or grouping of species that share a substantial structural feature as well as a common use that flows from the substantial structural feature, or present a sufficient showing that the species recited in the alternative of the claims(s) in fact share a substantial structural feature as well as a common use that flows from the substantial structural feature. This is a rejection on the merits and may be appealed to the Board of Patent Appeals and Interferences in accordance with 35 U.S.C. § 134 and 37 CFR41.31 (a) (1) (emphasis provided) Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 17-20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Instant claim 17 recites: “A method for treating a neurodegenerative disorder associated with dysregulation of MSUT2 signaling in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound having a structure represented by a formula: PNG media_image10.png 289 326 media_image10.png Greyscale ,” wherein the variables are defined in instant claim 17. In instant claim 17, it encompasses compounds that are not encompassed by instant claim 1 (see below for some examples): PNG media_image11.png 651 1040 media_image11.png Greyscale . Furthermore, the above four compounds are explicitly excluded from the formula recited in instant claim 1 and as disclosed in para. [00125] of the instant specification. Even though the instant specification discloses the section, “a. Treating a neurodegenerative disorder in a subject,” starting in para. [00247], the method being claimed (as recited in instant claim 17) is encompassing compounds that was explicitly excluded earlier in the instant specification in para. 00125. In other words, the scope of compounds encompassed by instant claim 17 is broader than the scope of compounds recited in para. 00125 of the instant specification. Moreover, it is unclear how Applicant can claim a method of using certain compounds that were explicitly excluded from the invention. Therefore, the scope of instant claim 17 is unclear and instant claim 17 is rendered indefinite. Claims 18-20, which are dependent on claim 17, are also rejected for further requiring and/or reciting the indefinite limitation of claim 17. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KRISTEN ROMERO whose telephone number is (571)272-6478. The examiner can normally be reached M-F 9:30 AM - 6:00 PM ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, JEFFREY H. MURRAY can be reached at (571) 272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KRISTEN W ROMERO/Examiner, Art Unit 1624 /JEFFREY H MURRAY/Supervisory Patent Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Mar 25, 2024
Application Filed
May 05, 2025
Response after Non-Final Action
May 20, 2026
Non-Final Rejection mailed — §102, §112
Aug 21, 2026
Response Filed
Oct 20, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788701
CERAMIDE GROWTH PROMOTING AGENT
4y 2m to grant Granted Nov 10, 2026
Patent 12790347
A CLASS OF FUSED RING COMPOUNDS, AND PREPARATION AND USE THEREOF
3y 7m to grant Granted Nov 10, 2026
Patent 12780826
POTENT AND SELECTIVE INHIBITORS OF HER2
3y 8m to grant Granted Nov 03, 2026
Patent 12767650
CRYSTAL FORM OF ENTRECTINIB AND PREPARATION METHOD THEREFOR
3y 2m to grant Granted Oct 20, 2026
Patent 12747229
PYRAZOLYL PYRIMIDINONE COMPOUNDS AND THE USES THEREOF
3y 6m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
70%
Grant Probability
99%
With Interview (+30.8%)
3y 2m (~6m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 54 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month